CTMX supply chain intelligence for CytomX Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AMGN | Amgen Inc. | 90% | In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| AMGN | Amgen Inc. | 90% | Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| BMY | Bristol-Myers Squibb Company | 90% | In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the "BMS Agreement") to discover and develop compounds for use in human therapeutics aimed at multiple imm… |
| BMY | Bristol-Myers Squibb Company | 90% | Reciprocal relationship from BMY graph: Reciprocal relationship from CTMX graph: In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the "BMS Agreement") to d… |
| MODERNA | MODERNA | 90% | In December 2022, we entered into a Collaboration and License Agreement (the "Moderna Agreement") with Moderna, pursuant to which we and Moderna will collaborate on the creation of mRNA-based conditi… |
| ABBV | AbbVie Inc. | 80% | Reciprocal relationship from ABBV graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from CTMX graph: For instance, in March 2023, AbbVie… |
| ABBV | AbbVie Inc. | 80% | For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement, and from time to time some of our research programs have been terminated by our partners. |
| ASTELLAS | ASTELLAS | 80% | In March 2026, Astellas chose to not advance the remaining preclinical programs under the alliance, resulting in a termination of the collaboration effective in the second quarter of 2026. |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from AZN grap… |
| AZN | AstraZeneca PLC | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| CELG-RI | CELG-RI | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2… |
| LLY | Eli Lilly and Company | 72% | s while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved ind… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: s while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the… |
| MRK | Merck & Co., Inc. | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX graph: ccess to our facility and initiate … |
| MYGN | Myriad Genetics, Inc. | 72% | ccess to our facility and initiate a work-from-home program limiting onsite activity to a substantially reduced level of laboratory research activities. Although we gradually increased our laboratory… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: source for their respective manufacturing and supplies. Failure of any of these contractors could affect our ability … |
| NKTR | Nektar Therapeutics | 72% | source for their respective manufacturing and supplies. Failure of any of these contractors could affect our ability to have clinical trial material available when needed and could result in substant… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, … |
| NVSEF | Novartis AG | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from REGN g… |
| SNYNF | Sanofi | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, … |
| IMMUNOGEN | IMMUNOGEN | 70% | Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics. |
| PFE | Pfizer Inc. | 70% | Reciprocal relationship from PFE graph: Reciprocal relationship from CTMX graph: Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna… |
| PFE | Pfizer Inc. | 70% | Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics. |
| REGENERON | REGENERON | 70% | Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AMGN | Amgen Inc. | 90% | In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| AMGN | Amgen Inc. | 90% | Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: In September 2017, we entered into … |
| BMY | Bristol-Myers Squibb Company | 90% | Reciprocal relationship from BMY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 90% | In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the "BMS Agreement") to discover and develop compounds for use in human therapeutics aimed at multiple imm… |
| MODERNA | MODERNA | 90% | In December 2022, we entered into a Collaboration and License Agreement (the "Moderna Agreement") with Moderna, pursuant to which we and Moderna will collaborate on the creation of mRNA-based conditi… |
| ABBV | AbbVie Inc. | 80% | For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement |
| ABBV | AbbVie Inc. | 80% | Reciprocal relationship from ABBV graph: Reciprocal relationship from CTMX graph: For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement |
| ASTELLAS | ASTELLAS | 80% | In March 2026, Astellas chose to not advance the remaining preclinical programs under the alliance, resulting in a termination of the collaboration effective in the second quarter of 2026. |
| AZN | AstraZeneca PLC | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we… |
| CELG-RI | CELG-RI | 72% | tol Myers Squibb amended the BMS Agreement and entered into Amendment Number 3 (“Amendment 3”), as previously amended by Amendment 1 and Amendment 2, to clarify the rights and restrictions of certain… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from LLY grap… |
| LLY | Eli Lilly and Company | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from MRK grap… |
| MRK | Merck & Co., Inc. | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| MYGN | Myriad Genetics, Inc. | 72% | and adverse effect on our business, financial condition, results of operations and prospects. Our employees and independent contractors may engage in misconduct or other improper activities, includin… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX graph: and adverse effect on our business, financial condition, results of operations and prospects. Our employees and indep… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NKTR g… |
| NKTR | Nektar Therapeutics | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSE… |
| NVSEF | Novartis AG | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from REGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish… |
| SNYNF | Sanofi | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CTMX-DEBT | Debt stack $2.9M | 90% | Market cache reports total debt of $2.9M. |
| CTMX-DEBT-8909 | Warrants outstanding: 81620 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CTMX-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 183 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 |